BudMaps

Legalizing Psychedelic Medicine
2017-10-07 23:00 - 2017-10-08 03:59 (America/Sao_Paulo)
You are invited to an evening soirée in Soho, New York.
Join the company of like-minded individuals, share your perspective among other trailblazers, enjoy a psychedelic comedy performance, and show your support for the legalization of psychedelic medicine.
Saturday, October 7, 2017
Doors open at 7:00 P.M.
Food served at 7:30 P.M.
Program begins at 9:00 P.M.
Speakers:
MAPS Founder and Executive Director, Rick Doblin, Ph.D., will host an illuminating conversation about how the path to legalizing psychedelic medicine leads to his vision of a post-prohibition world; where psychedelics are used as prescription medicines, as valuable tools for inspiring creativity, for personal and spiritual growth, and for catalyzing resolutions to global and social conflicts.
Author Rachel Hope overcame treatment-resistant PTSD after participating in MAPS’ Phase 2 clinical research. Rachel is now a public advocate for the legalization of this potentially life-saving therapy.
Shannon Clare Carlin, M.A., is investigating MDMA-assisted psychotherapy for PTSD as a co-therapist at the Phase 3 study site in Los Angeles, California. Shannon previously treated Phase 2 study participants for anxiety associated with life-threatening illness. Shannon serves as Therapy Training Program Manager, and oversees education for therapists.
Comedian Adam Strauss’ work has been called many things, mostly adjectives. The New York Times said The Mushroom Cure, Adam’s true account of his attempt to treat his severe OCD with psychedelics, “mines a great deal of laughter from disabling pain.” Time Out New York called it “riveting… a true-life tour de force” and named it a Critics’ Pick.
Breakthrough Therapy Designation
Preliminary studies have shown that MDMA combined with psychotherapy can help people overcome PTSD. After careful review of these studies, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to MDMA for the treatment of PTSD. By granting Breakthrough Therapy Designation, the FDA has agreed that this treatment may have a meaningful advantage and greater compliance over available medications for PTSD. Breakthrough Therapy Designation also means that the FDA will work closely with MAPS to complete Phase 3 trials, the final phase of research, as efficiently as possible.
Phase 3 trials require more clinical sites, more therapists, more patients, and more support. This research is crucial to receiving government approval of MDMA-assisted psychotherapy as a legal treatment, which would radically shift policy and public perception surrounding psychedelics.
Healing Trauma
Together, we can work to heal millions of people suffering from PTSD by supporting groundbreaking research into psychedelic therapies. This research is essential to obtaining government approval of MDMA-assisted psychotherapy as a legal treatment, which would radically shift policy and public perception surrounding psychedelics. There is a need unmet by modern psychiatry and psychotherapy that psychedelic-assisted therapies can fill.
We can create this future together. Join us in opening the doors to new models for healing and personal growth. Proceeds from the event benefit MAPS’ research and education programs. The first $20,000 donated on-site will be matched 2:1 by generous donors Laura and Ed Littlefield who pledged $40,000.
Special thanks to our hosts, Giancarlo and Stephanie Canavesio, and to host committee members Susan Brody, Sheila Burgel, Sir Ivan, Joshua Mailman and Monica Winsor, John McCormick, Stefanie Frank, Rodrigo Nino, Daniel Pinchbeck, Carey and Claudia Turnbull. Additional members to be announced.
This event coincides with the Horizons 2017: Perspectives on Psychedelics conference taking place in New York, New York, from October 6-8, 2017.
maps.org/nyc2017
For more information, contact the MAPS office at (831) 429-6362 or events@maps.org.
Learn about our research and other events at maps.org

Legalizing Psychedelic Medicine
2017-10-13 20:00 - 2017-10-14 00:59
You are invited to an evening soirée in Atlanta.
Join the company of like-minded individuals, share your perspective among other trailblazers, and show your support for the legalization of psychedelic medicine.
Speakers:
Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist.
Psychologist Barbara Rothbaum, Ph.D., is a leading PTSD researcher and currently serves as Principal Investigator of the ongoing MAPS-sponsored Phase 1 study on the effect of MDMA on startle testing in healthy volunteers, taking place at Emory University in Atlanta, Georgia.
MAPS Founder and Executive Director, Rick Doblin, Ph.D., will hold an illuminating conversation about how the path to legalizing psychedelic medicine leads to his vision of a post-prohibition world; where psychedelics are used as prescription medicines, as valuable tools for inspiring creativity, for personal and spiritual growth, and for catalyzing resolutions to global and social conflicts.
Leading researchers will join in the discussion to highlight the progress of MAPS-sponsored clinical trials investigating MDMA-assisted psychotherapy as a treatment for posttraumatic stress disorder (PTSD).
Breakthrough Therapy Designation
Preliminary studies have shown that MDMA combined with psychotherapy can help people overcome PTSD. After careful review of these studies, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to MDMA for the treatment of PTSD. By granting Breakthrough Therapy Designation, the FDA has agreed that this treatment may have a meaningful advantage and greater compliance over available medications for PTSD. Breakthrough Therapy Designation also means that the FDA will work closely with MAPS to complete Phase 3 trials, the final phase of research, as efficiently as possible.
Phase 3 trials require more clinical sites, more therapists, more patients, and more support. This research is crucial to receiving government approval of MDMA-assisted psychotherapy as a legal treatment, which would radically shift policy and public perception surrounding psychedelics.
Healing Trauma
There is a need unmet by modern psychiatry that psychedelic-assisted therapies can fill. By supporting groundbreaking research with psychedelic therapies, we can work together toward healing millions of people suffering from PTSD.
We can create this future together. Join us in opening the doors to new models for healing and personal growth. Proceeds from the event benefit MAPS’ research and education programs.
Special thanks to our host, Barbara Meyers, and our host committee member, Marsha Rosenbaum.
This event coincides with the International Drug Policy Reform Conference in Atlanta, Georgia, taking place from October 11-14, 2017.
maps.org/atlanta2017
For more information, contact the MAPS office at (831) 429-6362 or events@maps.org.
Learn about our research and other events at maps.org

Exibição documentário "Ilegal - A vida não espera" em Joinville
2017-10-14 19:00 - 22:00
Exibição do Filme Ilegal e Debate sobre Maconha Medicinal
Quando: 14/10, às 19hs
Onde: CasaZen Joinville R. XV de Novembro, 3269 – Centro, Joinville – SC, 89216-201
Quanto: Entrada Gratuita
Oque: Exibição do documentário “Ilegal: A vida não espera”,
Debatedores:
Alina Wallauer – Psicóloga e Redutora de Danos;
Amanda Santos – Terapeuta Quântica Transpessoal da Essência
Sergio Vidal – Antropólogo. Autor do Livro Cannabis Medicinal Introdução ao Cultivo Indoor;
Sobre o filme:
ILEGAL: A vida não espera (Direção: Raphael Erichsen e Tarso Araujo)
Filme registra o movimento de mães pela legalização de remédios derivados da maconha, proibidos no Brasil. De um lado, uma menina de 5 anos com uma forma de e pilepsia rara, grave e sem cura. Do outro, uma substância derivada da maconha que acaba com as convulsões da criança. Entre as duas, uma lei que torna o tratamento impossível.
ILEGAL mostra a luta de um grupo de mães contra a burocracia e o preconceito para garantir aos seus filhos o direito à saúde, e como seu exemplo deu origem a um movimento nacional pela legalização da Cannabis medicinal.
Ficha Técnica
Brasil, 2014, 90 min, 12 anos.
Direção: Raphael Erichsen e Tarso Araujo
Co-produção: 3FilmGroup.tv e Revista Superinteressante
Produção Executiva: Clarice Laus, Raphael Erichsen, Tarso Araújo
Direção de Fotografia: Braga
Direção de Edição: Tiago Berbare
Sinopse: Ilegal conta a história de como um grupo de mães que luta para tratar seus filhos com um remédio derivado da maconha se transformou em um ícone de mobilização social.
